Provides guidance to HCPs on the risks associated with teriflunomide and explains that patients should be regularly consulted about these risks. Potential risks are described as are monitoring methods. Risk of teratogenicity is described and that teriflunomide is contraindicated in pregnancy. Specific guidance on this subject is also offered.